Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SH) has announced the receipt of a clinical trial approval notice from the National Medical Products Administration for "KC1036 combined with PD-1/PD-L1 antibodies in the treatment of recurrent or metastatic advanced solid tumors." KC1036 is a Class 1 innovative chemical drug independently developed by the company, which holds global intellectual property rights for the product. The drug exerts its anti-tumor activity by inhibiting multiple targets, including VEGFR2 and AXL. KC1036 demonstrates potent VEGFR vascular targeting, inhibiting tumor cell growth. By suppressing AXL, it can enhance the host's anti-tumor immune response, thereby preventing tumor immune evasion.